TITLE

The effect of vapocoolant spray on pain due to intravenous cannulation in children: a randomized controlled trial

AUTHOR(S)
Farion, Ken J.; Splinter, Karen L.; Newhook, Kym; Gaboury, Isabelle; Splinter, William M.
PUB. DATE
July 2008
SOURCE
CMAJ: Canadian Medical Association Journal;7/1/2008, Vol. 179 Issue 1, p31
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Background: Established noninvasive pharmacologic means of alleviating pain and anxiety in children undergoing intravenous cannulation are time-consuming, and thus impractical for routine use in the emergency department. Vapocoolant sprays provide transient skin anesthesia within seconds of application. We compared the effect of a new vapocoolant spray to placebo on pain due to intravenous cannulation in children. Methods: In this double-blind randomized controlled trial, which we conducted between June 1 and Sept. 12, 2006, 80 children aged 6-12 years received either vapocoolant spray or placebo before cannulation. Children rated their pain using a 100-mm colour visual analogue scale. Secondary outcomes included success rate on first attempt at cannulation and pain ratings by the children's parents, nurses and child life specialists. Results: We found a modest but significant reduction in pain with the use of vapocoolant spray (mean difference 19 mm, 95% confidence interval [CI] 6-32 mm; p < 0.01). Cannulation on first attempt was more often successful with the use of vapocoolant spray (85.0%) than with placebo (62.5%) (mean difference 22.5%, 95% CI 3.2%-39.9%; p = 0.03). The number needed to treat to prevent 1 cannulation failure was 5 (95% CI 3-32). Parents (p = 0.04), nurses (p = 0.01) and child life specialists (p < 0.01) considered the children's pain to be reduced with the use of vapocoolant spray. Interpretation: The vapocoolant spray in our study quickly and effectively reduced pain due to intravenous cannulation in children and improved the success rate of cannulation. It is an important option to reduce childhood procedural pain in emergency situations, especially when time precludes traditional interventions.
ACCESSION #
32678890

 

Related Articles

  • Effectiveness of sucrose analgesia in newborns undergoing painful medical procedures. Taddio, Anna; Shah, Vibhuti; Hancock, Rebecca; Smith, Ryan W.; Stephens, Derek; Atenafu,7, Eshetu; Beyene, Joseph; Koren, Gideon; Stevens, Bonnie; Katz, Joel // CMAJ: Canadian Medical Association Journal;7/1/2008, Vol. 179 Issue 1, p37 

    Background: Sucrose is widely used to manage procedural pain in term newborns despite a lack of evidence of its effectiveness for different procedures and infant populations. Our objectives were to evaluate the effectiveness and safety of sucrose in newborns undergoing various medical procedures...

  • Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. Yenrudee Poomtavorn; Vorapong Phupong // Archives of Gynecology & Obstetrics;Dec2005, Vol. 273 Issue 2, p115 

    Objective: To evaluate the analgesic efficacy of preoperative rofecoxib in patients who underwent uterine curettage. Materials and methods: This double-blinded, randomized, placebo-controlled trial included 80 women who underwent uterine curettage. Forty women were randomly assigned to rofecoxib...

  • Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography. Chung, Seen; Lim, Ruth; Goldman, Ran D. // Pediatric Radiology;Jul2010, Vol. 40 Issue 7, p1236 

    Voiding cystourethrogram (VCUG) is a common procedure at pediatric tertiary care centres that can be painful as it involves a urinary catheter. Currently there are no widely utilized protocols for non-topical medications to decrease pain that children feel during catheterization. To determine if...

  • Janssen announces encouraging results from Phase III DPN study.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p37 

    The article reports on the announcement of Janssen Pharmaceuticals Inc. on the results of a Phase III study for diabetic peripheral neuropathy (DPN) treatment. It suggests that Nucynta Er or tapentadol tablets were more effective than placebo in providing pain management among adults with...

  • Concept Proven: Array Hits Analgesic Endpoint in Phase II. Shaffer, Catherine // BioWorld Today;8/2/2012, Vol. 23 Issue 149, p1 

    The article reports that the p38-alpha kinase inhibitor ARRY-797 of Array BioPharma Inc. has hit its primary endpoint of reducing pain more than placebo in a Phase II proof-of-concept trial. The trial involved 157 patients afflicted with moderate-to-severe pain in spite of the use of...

  • Flecainide for the treatment of chronic neuropathic pain: a Phase II trial: Eastern Co-operative Oncology Group Study E1Z95. von Gunten, Charles F.; Eappen, Sarah; Cleary, James Francis; Taylor IV, Samuel G.; Moots, Paul; Regevik, Nina; Cleeland, Charles; Cella, David // Palliative Medicine;Dec2007, Vol. 21 Issue 8, p667 

    Background: Management of neuropathic pain is challenging. Medications that interfere with sodium channel transport, such as lidocaine, mexilitene and flecainide, are promising as analgesics. Objective: In a general population of patients with a working diagnosis of neuropathic pain, whether if...

  • Effects of Guanfacine Extended Release on Oppositional Symptoms in Children Aged 6-12 Years with Attention-Deficit Hyperactivity Disorder and Oppositional Symptoms. Connor, Daniel F.; Findling, Robert L.; Kollins, Scott H.; Sallee, Floyd; Lopez, Frank A.; Lyne, Andrew; Tremblay, Gerald // CNS Drugs;2010, Vol. 24 Issue 9, p755 

    Objective: To evaluate the efficacy and safety of guanfacine extended release (XR, Intunivâ„¢; Shire Development Inc., Wayne, PA, USA) in the treatment of oppositional symptoms in children aged 6-12 years with a diagnosis of attention-deficit hyperactivity disorder (ADHD) and the presence of...

  • Treatment of Tourette syndrome with cannabinoids. Müller-Vahl, Kirsten R. // Behavioural Neurology;2013, Vol. 27 Issue 1, p119 

    Cannabinoids have been used for hundred of years for medical purposes. To day, the cannabinoid delta-9-tetrahydrocannabinol (THC) and the cannabis extract nabiximols are approved for the treatment of nausea, anorexia and spasticity, respectively. In Tourette syndrome (TS) several anecdotal...

  • Atomoxetine and suicidal thinking in children and adolescents.  // WHO Drug Information;2005, Vol. 19 Issue 4, p294 

    The article provides information on the approval of the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adult patients. The information include the warning statements of an increased risk of suicidal thinking in children and adolescents. An increased risk of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics